ReviewNature reviews. Nephrology2025
Antigens in membranous nephropathy: discovery and clinical implications.
Review in Nature reviews. Nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.International urology and nephrology · 2026Review
- Coexistence of ANCA-associated glomerulonephritis and membranous nephropathy: a scoping review.Clinical and experimental nephrology · 2026Article
- Association between anti-PLA2R antibody status and clinical remission in primary membranous nephropathy: a systematic review and meta-analysis.International urology and nephrology · 2026Review
- Atlas of glomerular disease-specific genetic effects on blood transcriptome.medRxiv : the preprint server for health sciences · 2026Article
- Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia.Kidney medicine · 2026Article
- Semaphorin 3B-Membranous Nephropathy in Adults.Kidney international reports · 2026Article
- Complement Profiling in Glomerular Disease: Insights from Laser Microdissection and Mass Spectrometry.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Detection of Exostosin 1 in Lupus Nephritis: Prevalence, Clinico-Pathologic and Renal Outcome Correlations.Diagnostics (Basel, Switzerland) · 2026Article
- Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation.Kidney international reports · 2026Review
- Autoimmune nodopathy associated with Sjögren's disease and nephrotic syndrome: a case report and literature review.Frontiers in immunology · 2026Review
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
- Liver-kidney crosstalk in primary biliary cholangitis: insights into the mechanisms of renal involvement.Frontiers in immunology · 2026Review
- Kidney-targeted drug delivery: from physiological mechanisms to precision therapeutics.Frontiers in bioengineering and biotechnology · 2026Review
- Risk prediction of PLA2R-Ab-negative membranous nephropathy: an interpretable multicenter machine learning model.Frontiers in immunology · 2026Article
- Thromboembolism in the left main coronary artery of a patient with membranous nephropathy: a case report.Frontiers in cardiovascular medicine · 2026Article
- Long-term outcomes in primary membranous nephropathy: a Chinese cohort study with novel target antigen.Frontiers in immunology · 2026Article
- Molecular immunopharmacology of traditional Chinese medicine-derived compounds in membranous nephropathy: mechanistic insights into immune aging and kidney essence deficiency.Frontiers in immunology · 2026Review
- Urinary betaine/creatinine ratio enhances diagnostic accuracy of PLA2R-Ab in idiopathic membranous nephropathy.BMC nephrology · 2025Article
- Melanocortins: A new paradigm in immunotherapy for membranous nephropathy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous nephropathy is an autoimmune disease that results in an accumulation of antigen-antibody (IgG) immune complexes along the subepithelial region of the glomerular basement membrane and is the most common cause of nephrotic syndrome in adults. The diagnosis of membranous nephropathy is based on the presence of granular IgG on immunofluorescence microscopy and subepithelial electron dense deposits along the glomerular basement membrane on electron microscopy. Prior to 2009, the target antigen within the immune complexes was unknown. However, in the past 15 years, and in particular the past 5 years, several target antigens have been identified. These target antigens include PLA2R, THSD7A, EXT1 and EXT2, NELL1, SEMA3B, NCAM1, CNTN1, HTRA1, FAT1, PCDH7, NTNG1, PCSK6, NDNF and MPO. Several rare putative antigens have also been reported. These findings have transformed our understanding of membranous nephropathy from that of an idiopathic disease, which results from an autoimmune response to an unknown target antigen, to a disease in which a target antigen can be identified in ~80% of cases. Improved understanding of the distinctive clinical association, pathology and prognostic findings of each target antigen will have implications for clinical evaluation and therapeutic targeting in patients with membranous nephropathy.
Indexed as
Identifiers
40691733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.